Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
DiaCarta, Inc. logo — Redefining Precision Molecular Diagnostics through Cancer Ge...

DiaCarta, Inc.

Redefining Precision Molecular Diagnostics through Cancer Gene Mutation Detection

Founded 2012 United States Pleasanton, United States 40 employees Series B Total: $53.00M Biotechnology

General Information

Company Name DiaCarta, Inc.
Founded Year 2012
Location United States Pleasanton, United States
Employees 40
Industries Biotechnology
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with DiaCarta, Inc.. To contact DiaCarta, Inc., visit diacarta.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does DiaCarta, Inc. compare?

A PDF of DiaCarta, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting DiaCarta, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About DiaCarta, Inc.

DiaCarta, Inc. is a biotechnology startup that has been shaping the future of precision molecular diagnostics since its inception in 2011. The company's slogan, "Redefining Precision Molecular Diagnostics through Cancer Gene Mutation Detection," reflects its mission to revolutionize cancer diagnosis, therapy identification, and prognosis monitoring. DiaCarta's focus on translational genomics and personalized diagnostics is evident in its provision of ultra-sensitive detection tools. This emphasis aligns with the global goal of impacting healthcare treatment plans and individuals' well-being. In 2018, DiaCarta secured a significant $45.00M Series B investment, an indicator of investor confidence in the company's potential and vision. Noteworthy entities such as Fortune Fountain Capital and Good Health Capital (GHC) contributed to this landmark investment. DiaCarta's headquarters is located in the United States, positioning the company within the heart of innovation and advancement in the biotechnology industry. With its cutting-edge technologies and unwavering dedication to impacting healthcare, DiaCarta is poised to solidify its position as a leader in the field of precision molecular diagnostics. For further information, individuals can visit DiaCarta's website at http://www.diacarta.com.

Business keywords: Precision Molecular Diagnostics, Translational Genomics, CLIA Lab, Liquid Biopsy, Cancer Mutation Detection, Colorectal Cancer Mutation Detection, In-Vitro Diagnostics, Precision Medicine, Personalized Radiation Therapy, HPV mRNA Test, Cervical Cancer Screening, Head and Neck Cancer Screening, Early Cancer Detection, NGS (Next-Generation Sequencing), SuperbDNA Technology

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $45.00M 2
Fortune Fountain Capital, Good Health Capital(GHC)
12 Feb 2018
Series A $8.00M 1
BVCF Management
BVCF Management
09 Jan 2015

DiaCarta, Inc. Alternatives & Competitors

View All Alternatives
DiaCarta, Inc. vs
Geneseeq Technology Inc.
Geneseeq Technology Inc. Canada

Cancer: a word, not a sentence!

Series D
32 employees
Biotechnology, Health Care
DiaCarta, Inc. vs
Predicine
Predicine United States

Advancing precision medicine through next-generation liquid biopsy oncology platform

89 employees
Biotechnology, Health Care
DiaCarta, Inc. vs
SAGA Diagnostics
SAGA Diagnostics United States

Redefining the early detection of molecular residual disease (MRD).

Series A
97 employees
Biotechnology
Compare DiaCarta, Inc. vs SAGA Diagnostics
View all alternatives

FAQ About DiaCarta, Inc.

Redefining Precision Molecular Diagnostics through Cancer Gene Mutation Detection
DiaCarta, Inc. was founded in 2012.
DiaCarta, Inc. is headquartered in Pleasanton, United States.
DiaCarta, Inc. operates in Biotechnology. Its work centres on Precision Molecular Diagnostics, Translational Genomics, CLIA Lab and Liquid Biopsy.
DiaCarta, Inc. has approximately 40 employees.
DiaCarta, Inc. has completed 2 funding rounds, raising a total of $53.00M. The latest funding stage is Series B.
Top alternatives and competitors to DiaCarta, Inc. include Geneseeq Technology Inc., Predicine, SAGA Diagnostics, LCM Genect, Geninus Inc. . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DiaCarta, Inc. and Geneseeq Technology Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for DiaCarta, Inc., https://bouncewatch.com/company/diacarta-inc, updated 29 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes